Photographic portrait of Subin Baral
The need for innovation to achieve future growth targets will drive the biopharma M&A activities, mainly strategic partnerships and bolt-on acquisitions.

Subin Baral

EY Global Life Sciences Deals Leader

Committed to helping life sciences companies create focused business models that outperform. Loves road trips and the outdoors.

Subin is a Partner at Ernst & Young LLP and the EY Global Life Sciences Deals Leader. He has more than a decade of transaction experience, helping life sciences companies with transformational transactions.

Subin has extensive global experience serving as a buy- and sell-side transaction advisor for Fortune 500 companies, including in corporate and private equity. His experience includes working with companies in the pharmaceutical, medical device and biotechnology subsectors.

Subin focuses on acquisitions, carve-outs, spin-offs and initial public offerings and works with companies at all stages of maturity, from startups to public companies. He frequently speaks at life sciences events about sector trends and acquisitions and divestitures topics.

He received his Master of Commerce from Macquarie University in Sydney, Australia. He is a chartered accountant from the Institute of Chartered Accountants of Australia and New Zealand.

How Subin is building a better working world

"I am helping to build a better working world by advising global life sciences companies of all sizes on how to remain agile at a time of dynamic change. By asking better questions, I work closely alongside these companies to help them create new high-growth investment and portfolio optimization opportunities."

Contact Subin